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Abstract
Atypical haemolytic uraemic syndrome (aHUS) is a rare, life-threatening, chronic, genetic disease due to uncontrolled
alternative pathway complement activation. In this report, we discuss the case of a heterozygous carrier of a mutation on both
factor H and membrane cofactor protein, who persistently presents haemolytic anaemia without need for blood transfusions,
normal platelet count, normal renal function and no signs or symptoms of organ injury due to thrombotic microangiopathy
4 years after the diagnosis of aHUS.
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Introduction
Atypical haemolytic uraemic syndrome (aHUS) is a rare, life-
threatening, chronic, genetic disease due to uncontrolled alter-
native pathway complement activation [1]. In most cases, aHUS
is associated with mutations or polymorphisms in the genes
CFH (encoding complement factor H), accounting for 11–29%,
CD46 (MCP, membrane cofactor protein) 3–17% and CFI (encoding
complement factor I) 2–17% [2]. Mutations inmore than one com-
plement gene have been identiﬁed in some patients, and
nucleotide polymorphisms in CFH and MCP genes can modulate
the risk of aHUS in mutation carriers [3].
Case report
A 31-year-old female presented in our hospital with abdominal
pain. The investigations performed showed gallbladder infection
and microangiopathic haemolytic anaemia, thrombocytopaenia
and acute kidney injury. She had a past medical history of kidney
stones and one uneventful pregnancy, and no previous history of
diarrhoea. She had no family history of kidney disease or aHUS.
Initial investigation revealed the following: haemoglobin 8.3 g/L,
platelet count 140 × 106/μL and serum creatinine 3.8 mg/dL.
A peripheral blood smear revealed fragmented red cells consistent
with thrombotic microangiopathy. The gallbladder infection was
treated with broad-spectrum antibiotics with resolution of symp-
toms. Despite this, after 2 days she became thrombocytopaenic
(73 × 106/μL), and serum creatinine rose to 4.8 mg/dL accompanied
by haematuria and proteinuria. Plasma exchange (PE) with fresh
frozen plasmawas promptly started. Her course was complicated
with ﬂuid overload and oliguria, leading to the need to perform a
brief period of haemodialysis. Following nine sessions of PE over
a period of 2 weeks, her parameters improved (haemoglobin
12.4 g/dL, platelet count 220 × 106/μL, lactate dehydrogenase (LDH)
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1054 U/L, serum creatinine 1.1 mg/dL). The study performed at
presentation showed normal ADAMTS13 activity and C3 serum
levels. The patient was clinically diagnosed with aHUS, possibly
triggered by the gallbladder infection. After 4 years, her renal
function and platelet number arenormal, but the patient has per-
sistent microangiopathic haemolytic anaemia (Table 1). Despite
analytical parameters of haemolysis (LDH 1554 U/L, indirect bili-
rubin 1.54 mg/dL and absent haptoglobin), the patient has no
signs or symptoms of organ injury/thrombosis, no hypertension,
no proteinuria and the haemoglobin levels remain stablewith no
need for blood transfusion. During these 4 years, the patient had
possible triggering events (infection and cholecystectomy), with
no relapse of aHUS. In keeping with this, we performed a genetic
analysis to investigate whether the patient carried some genetic
abnormalities associated with aHUS. Mutation screening of CFH,
MCP and CFI by Sanger sequencing revealed two heterozygous
mutations: a CFH (c.3493 C>T, p.His1165Tyr) and an MCP (c.1058
C>T, pAla353Val). The ﬁrst amino acid substitution is not de-
scribed, and the second is known as a disease mutation [4, 5].
Discussion
aHUS is a challenging disease to manage with a relatively poor
prognosis, as up to 65% of patients treated with PE will sustain
permanent renal damage, have progression to end-stage renal
disease (ESRD) or diewithin 1 year [6]. In the past years, it became
evident that aHUS is associated with mutations in proteins
needed for regulation of the alternative complement pathway
[7]. Because of the multiple genetic susceptibility factors involv-
ing plasma- and membrane-associated regulators, the rarity of
combined-mutated patients and the need for a triggering event,
it is difﬁcult to predict the clinical course of aHUS. The combined
CFH/MCP mutations reported in our patient (CFH p.His1165Tyr/
MCP pAla353Val) have not been previously described. As previ-
ously reported, it seems that MCP or CFH mutations confer a
predisposition to develop aHUS rather than directly cause the
disease, and a second hit is necessary for the full-blown
manifestation of the disease, as in all MCP-mutated and 70% of
CFH-mutated patients the onset of aHUS was associated with
an infectious event [4]. Our patient showed an impaired capacity
to protect vascular endothelial cells from complement attack
after the activation caused by the gallbladder infection that led
to aHUS presentation. After that, the clinical course was clearly
distinct from patients with other CFH mutation and was similar
to patients with MCP mutations described previously. It has
been reported that the most severe prognosis is in the CFH
mutation patients, with 70% reaching ESRD, and that patients
with MCP mutations have a relapsing course, but none have
reached ESRD in the ﬁrst year [8]. In cases of combinedmutations
carriers, the concomitant presence of CFH and MCP risk haplo-
types signiﬁcantly increased disease penetration and modiﬁed
the prognosis [5]. Among patients with CFHmutations, the pres-
ence of mutations in other genes did not modify prognosis; how-
ever, 50% of patients with combined MCP mutation developed
ESRD within 3 years from onset compared with 19% of patients
with an isolated MCP mutation [5]. These two mutations (CFH p.
His1165Tyr/MCP pAla353Val) have a benign phenotype predic-
tion (Polyphen-2), and MCP pAla353Val has polymorphic preva-
lence (1000 Genomes Project). Despite that, their cumulative
effect confers a background genetic that seems to be a risk for
aHUS; however, their benign character explains the mild clinical
course. Indeed, the response to PEwould not be expected to be ef-
fective for patients with mutations in MCP, a transmembrane
protein that is not removed by this treatment, but patients with
combined mutations achieved remission with PE similar to pa-
tients with single non-MCPmutations [9]. The excellent response
of our patient could be related to the replacement of CFH proteins
with PE. In our patient, it seems that the mutated expressed pro-
teins cannot fully protect vascular endothelial cells from acti-
vated complement translated by the persistently haemolytic
microangiopathic anaemia; however, the regulation of the com-
plement attack is enough to protect her from a relapse.
In summary, we describe the ﬁrst reported case of aHUS with
the combination of a previously described MCP mutation with a
new CFH mutation associated with a rare clinical outcome (per-
sistent haemolysis without renal failure or any other clinical
manifestations of endothelial damage or platelet activation).
We may therefore speculate that combination of these frequent
mutations will worsen the phenotype and could be a common
but under-diagnosed phenomenon. The ﬁndings in this patient
underscore the inﬂuence of different genetic abnormalities on
disease presentation, response to therapy and outcome in
aHUS patients.
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Table 1. Variations on biochemical parameters during the 4-year follow-up
Hospital discharge
Time from hospital discharge
1 month 6 months 12 months 18 months 3 years 4 years
Serum creatinine (mg/dL) 2.8 1.1 0.7 0.5 0.6 0.5 0.7
Haemoglobin levels (g/dL) 12.0 12.4 11.7 11.2 10.6 11.3 10.4
Platelet count (cells × 106/μL) 190 262 253 254 269 195 193
LDH (U/L) 903 1054 774 942 850 972 1554
Serum haptoglobin (g/L) <10 <10 <10 <10 <10
UPCR (mg/mg) 0.65 0.14 0.07 0.06 0.01 0.08 0.05
Complement C3 (mg/dL) 96.8 77.2
Complement C4 (mg/dL) 21.8 15.7
Homocysteine levels (μmol/L) 10.0
UPCR: protein–creatinine ratio on random urine sample.
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